Pharming Group N.V. has announced a major milestone with the approval of its treatment Joenja for children with activated PI3K delta syndrome (APDS) in the U.K. The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the marketing authorization for Joenja to include children aged 4 to 11 years who weigh at least 27 kg. This approval is significant as it marks the first treatment specifically for this age group in the U.K., enhancing Pharming's position in the pharmaceutical preparations industry.
Pharming, a global biotechnology company based in Leiden, Netherlands, focuses on developing innovative medicines for rare immune and genetic diseases. The company trades on both Euronext Amsterdam under the ticker PHARM and on Nasdaq under PHAR. Pharming's recent filings include a series of 6-K forms, with the latest dated November 6, 2026, detailing this important approval.
The filing indicates that Joenja is now approved for pediatric patients, expanding upon its previous authorization for adults and adolescents aged 12 years and older. The company plans to make Joenja available to eligible patients by February 2027 and is working closely with the National Health Service (NHS) to ensure timely access.
According to the filing, the approval includes dosing options of 40 mg and 50 mg twice daily for eligible children. Leverne Marsh, interim Co-CEO and Chief Commercial Officer of Pharming, emphasized the importance of this approval, stating, "This approval is the latest step in our continued expansion of Joenja across age groups and geographies, giving eligible children in the U.K. aged 4 to 11 with APDS an approved treatment option."
This development is expected to have a significant impact on families affected by APDS, a rare primary immunodeficiency that can lead to serious health complications. Dr. Austen Worth, a Pediatric Immunology Consultant at Great Ormond Street Hospital, noted, "The extension of the marketing authorization for leniolisib to children as young as four years old represents a significant step forward for children and families living with APDS."
The MHRA's decision was supported by data from Pharming's pediatric clinical program, which was part of a Pediatric Investigation Plan (PIP) agreed upon with the agency. The data demonstrated that leniolisib was generally well-tolerated in patients aged four and above, reinforcing a positive benefit-risk profile in this age group.
Looking ahead, Pharming is likely to continue its efforts to expand Joenja's availability across other markets and age groups. The filing does not specify what further actions the company will take following this approval, but it is clear that Pharming is committed to supporting access for younger patients.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










